Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT — Stella

Recruiting

Back to Hematopoietic Stem Cell Transplantation trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang

Key details

Phase

Large-scale testing

Sponsor

First Affiliated Hospital of Zhejiang University

Enrollment target

~404 participants

Started

December 2025

Primary completion

October 2027

Age range

18 Years – 70 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov